Cargando…

Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer

OBJECTIVE: Regorafenib is a multikinase inhibitor, the effectiveness of which was demonstrated in metastatic colorectal cancer. This study aimed to investigate the factors that could predict the effectiveness of regorafenib. MATERIALS AND METHODS: This study retrospectively reviewed the clinical cha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebinç, Senar, Oruç, Zeynep, Urakçi, Zuhat, Kalkan, Ziya, Kaplan, Muhammet Ali, Küçüköner, Mehmet, Işikdoğan, Abdurrahman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Atatürk University School of Medicine 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797696/ https://www.ncbi.nlm.nih.gov/pubmed/35950825 http://dx.doi.org/10.5152/eurasianjmed.2022.21162

Ejemplares similares

Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
por: Urakçı, Zuhat, et al.
Publicado: (2023)

Prognostic factors and the prognostic role of inflammation indices in malignant pleural mesothelioma
por: Ebinç, Senar, et al.
Publicado: (2023)

Neoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Cancer
por: Ebinç, Senar, et al.
Publicado: (2023)

The importance of serum and pleural fluid level of vascular endothelial growth factor (VEGF) and VEGF fluid/serum ratio in the differential diagnosis of malignant mesothelioma-related pleural effusion
por: Düzköprü, Yakup, et al.
Publicado: (2017)

Testicular Mass: An Initial Sign of Squamous Cell Carcinoma of the Lung
por: Kaplan, Muhammet Ali, et al.
Publicado: (2012)

Germ Cell Tumor Located in Gastrointestinal System: A Report of Two Cases
por: Kucukoner, Mehmet, et al.
Publicado: (2012)

Is there any significance of lung cancer histology to compare the diagnostic accuracies of (18)F-FDG-PET/CT and (99m)Tc-MDP BS for the detection of bone metastases in advanced NSCLC?
por: Inal, Ali, et al.
Publicado: (2014)

Epidemiological and clinical characteristics of malignant melanoma in Southeast Anatolia in Turkey
por: Sula, Bilal, et al.
Publicado: (2016)

Tumor lysis syndrome during radiotherapy for prostate cancer with bone and bone marrow metastases without visceral metastasis
por: Kaplan, Muhammet Ali, et al.
Publicado: (2012)

Treatment of gastrointestinal stromal tumors: A single-center experience
por: Ebinc, Senar, et al.
Publicado: (2021)

Clinical characteristics and treatment outcomes in 132 patients with malignant mesothelioma
por: Abakay, Abdurrahman, et al.
Publicado: (2011)

Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology
por: Mehmet, Kucukoner, et al.
Publicado: (2014)

Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?
por: Kucukoner, Mehmet, et al.
Publicado: (2012)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib
por: Arai, Hiroyuki, et al.
Publicado: (2017)

Effect of exercise on colorectal cancer prevention and treatment
por: Oruç, Zeynep, et al.
Publicado: (2019)

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study
por: Aljubran, Ali, et al.
Publicado: (2019)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer
por: Lim, Yoojoo, et al.
Publicado: (2015)

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022)

KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2016)

Differentiation of Tuberculous Peritonitis from Peritonitis Carcinomatosa without Surgical Intervention
por: Kaya, Muhsin, et al.
Publicado: (2011)

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
por: Khan, Gazala, et al.
Publicado: (2014)

Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report
por: KAWASAKI, KENTA, et al.
Publicado: (2016)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
por: Xue, Wu-Song, et al.
Publicado: (2018)

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
por: Yoshino, Kenji, et al.
Publicado: (2017)

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
por: Xu, Donghao, et al.
Publicado: (2022)

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer
por: Lee, Dae-Won, et al.
Publicado: (2023)

Evaluation of outcome and prognostic factors in 739 patients with uterine cervix carcinoma: a single institution experience
por: Teke, Fatma, et al.
Publicado: (2015)

Presence of paroxysmal nocturnal hemoglobinuria in patients with idiopathic portal vein thrombosis: a single-center study
por: DEMiR, Cengiz, et al.
Publicado: (2020)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2020)

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report
por: Tang, Ronald, et al.
Publicado: (2015)

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
por: Giampieri, Riccardo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_650mi60cf13t0v45k9bf6fu4ll